Chicago filed a lawsuit against five pharmaceutical companies, accusing them of concealing the risks associated with certain painkillers. » Read More
With the financial woes of Europe making rival US banks more attractive to investors, should you get long now?
Stocks traded sideways on Thursday as investors struggled to make sense out of this fickle market. What must you know?
According to the weekly survey by the American Association of Individual Investors, 49 percent of participants were still bearish. Mark Travis, CEO of Intrepid Capital Funds, and Paul Alan Davis, senior portfolio manager at Charles Schwab Investment Management, discussed what must be done to get investors off the sidelines.
The Lightning Round is extended in this CNBC.com exclusive feature.
Despite the market rally, portfolio manager Harry Rady of Rady Asset Management said he remains “more bearish than he’s ever been” and is continuing to take chips off the table. And Greg Olsen of Lenox Partners said he expects a pullback soon.
Cramer makes the call on viewers' favorite stocks.
Will M&A activity boost biotech stocks in 2009?
When it comes to where investors should put their money now, Delphi Management's Scott Black is very specific.
I thought I was finished with the post-Pfizer analyst meeting reaction with yesterday's post, but when an extraordinarily bearish 77-page research note from Credit Suisse big pharma analyst Catherine Arnold arrived in my inbox this morning, I had to do one more installment. She thinks Pfizer should buy Wyeth or Amgen...
Good morning. Chinese gaming stocks are in the spotlight Monday as The9 propelled Nancy Beaumont to the top of the pack on its 10.31% gain. The9 was up on the news that Electronic Arts agreed to buy a $167M stake in the company, and also licensed a soccer game to The9. Steven Lee managed to hold onto second even though he was all in cash after Friday's trading. He has now gone all-in on Neurochem.